Koninklijke Philips (PHG) DIvidends Date & History

Key Takeaways

• Philips (PHG) provides a trailing dividend yield of 3.23% and a forward yield of 3.87%, paid annually.
• Recent annual dividend per share stands at $0.85, with a proposed increase to $1.01 for 2026.
• Payout ratio of approximately 92% is elevated but supported by positive free cash flow of $453 million (trailing twelve months).
• Dividend payments resumed in 2025 after a pause in 2023-2024, showing two years of consecutive increases.
• Yield exceeds peers like GE HealthCare (GEHC) at 0.2% and aligns competitively with Medtronic (MDT) around 3%.
• Suitable for income-focused investors tolerant of sector cyclicality.

Dividend Overview

Philips (PHG), a global leader in health technology and medical devices, follows an annual dividend policy aiming for 40% to 50% of adjusted net income. The company currently offers a trailing annual dividend of $0.85 per share, yielding 3.23% based on recent stock prices. The forward dividend is projected at $1.01 per share, pushing the yield to 3.87%. Payments occur once yearly, typically with an ex-dividend date in mid-May and payment in early June. The next ex-dividend date is May 13, 2026, with payment on June 3, 2026. Philips is neither a high-yield nor rapid-growth dividend stock but provides a modest, reliable payout appealing to conservative income seekers in the healthcare sector.

Dividend History and Growth

Philips has maintained a history of annual dividends, with payments typically around $0.80 to $1.00 per share for the ADR. Recent payouts include $0.97 in May 2025 (ex-date May 13), $0.84 in 2022, and $1.03 equivalent in 2021. The company paused dividends in 2023 and 2024 amid financial pressures from product recalls and restructuring costs. Resumption in 2025 marked the start of two consecutive years of increases, with a 4.7% rise proposed for 2026. Over longer periods, the five-year average yield is 2.64%, reflecting modest growth of about 1.8% CAGR over 10 years. This profile indicates consistency outside of exceptional challenges, without a long dividend growth streak.

Dividend Sustainability and Payout Ratio

The current payout ratio stands at 91.68%, higher than the company's 40-50% target on adjusted net income, signaling potential pressure but coverage by fundamentals. Trailing twelve-month net income available to common shareholders is $899 million, with diluted EPS at $1.09. Levered free cash flow (FCF) of $453 million provides adequate coverage for the dividend. Debt-to-equity ratio is 73.57% (most recent quarter), manageable for the sector, and current ratio of 1.32 supports liquidity. While the elevated payout warrants monitoring, positive FCF and earnings recovery post-recall enhance sustainability.

Dividend Compared to Industry Peers

In the medical devices and health technology sector, Philips' 3.3% yield outperforms many peers. GE HealthCare (GEHC) yields just 0.2%, Stryker (SYK) around 1%, and Abbott Laboratories (ABT) about 1.8%. Medtronic (MDT) offers a comparable 3% yield. Philips' profile stands out for income in a sector often featuring lower or no dividends, driven by reinvestment needs, making PHG relatively attractive for yield comparison.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is particularly useful for identifying dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your investment strategy.

Is This Stock Attractive for Dividend Investors?

Philips (PHG) may appeal to income investors seeking above-average yields in health technology, where many peers offer minimal payouts. Its 3.3% yield provides steady cash flow, supported by annual payments and recent resumption after a pause. Dividend growth investors might find the modest 1-5% CAGR and short two-year streak less compelling compared to aristocrats. Conservative long-term holders could value the company's market leadership in diagnostics and patient monitoring, with FCF coverage mitigating high payout risks. However, exposure to regulatory recalls and cyclical healthcare demand requires tolerance for volatility. Balanced portfolios diversifying across medical devices may benefit, weighing yield against sector stability.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations